Rapid Manufacture and Isolation of Highly Viable Interferon- γ Expressing Virus-Specific T Cells: Validation Results for the Virus-Specific Cytotoxic T-Lymphocyte Consortium for Refractory EBV, CMV, and Adenovirus Infections

Children and young adults who develop treatment-refractory infection with EBV, CMV, and/or adenovirus (AdV) after allogeneic hematopoietic stem cell transplant (allo-HSCT) have a dismal prognosis ( ≥90% mortality). Adoptive transfer of ex-vivo expanded virus-specific cytotoxic T lymphocytes (CTLs) is a treatment option for these patients, but the cell manufacturing process is labor-intensive and typically takes several weeks of culturing to complete. More recently, a culture-free method has been developed to directly isolate virus-specific T cells from peripheral blood for adoptive transfer.

Source: Biology of Blood and Marrow Transplantation - January 31, 2019 Category: Hematology Authors: Stephan Kadauke, Bryon D. Johnson, Lauren Harrison, Lynn C. O'Donnell, Youwei Wang, Janet Ayello, Julie-An M. Talano, Dean Lee, Nancy J. Bunin, Yongping Wang, Mitchell S. Cairo Tags: 545 Source Type: research